Adverse events in IBD therapy: the 2018 update

Quezada, Sandra; McLean, Leon; Cross, Raymond K.

doi:10.1080/17474124.2018.1545574

Cited by 59 publications

(58 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, monitoring IFX-TLs and antibodies to IFX (ATIs) could be useful for predicting or preventing possible AEs of IFX. 8 Especially when IFX is used in combination with an immunomodulator, the risk of some AEs may be increased, 9 and the close monitoring of IFX-TLs could be valuable.…”

Section: Introductionmentioning

confidence: 99%

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

et al. 2021

View full text Add to dashboard Cite

been used in IBD for the last 20 years, and the first approved drug was infliximab (IFX). IFX has been established as an effective therapy from moderate to severe IBD, and it is used both as induction and maintenance treatment. 3 Anti-TNF agents are widely used in patients with IBD, both for the induction of remission and maintenance treatment. Sometimes it is necessary to use intensified regimens of therapy to achieve remission. Higher IFX trough levels (IFX-TLs) have been associated with higher rates of remission, but we always consider the probability of toxicity of the drugs when dose adjustment is required. 4 Many adverse events (AEs) have been described. Some of them require further medica

show abstract

Section: Introductionmentioning

confidence: 99%

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Next is chloramphenicol, an antibiotic used in the treatment of cholera and in eye drops or ointment to treat bacterial conjunctivitis 36 . Although it is linked to some adverse events, 38 azathioprine is used to treat inflammatory conditions, such as rheumatoid arthritis, and as an immunosuppressant in renal transplants. Papaverine is a safe direct‐acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation 39 .…”

Section: Discussionmentioning

confidence: 99%

Existing bitter medicines for fighting 2019‐nCoV‐associated infectious diseases

Zhang

Liu

et al. 2020

FASEB j.

View full text Add to dashboard Cite

show abstract

“…We conducted a sensitivity analysis, where biologic therapy was given without a course of prednisone, as prednisone can be avoided in some circumstances due to the more rapid onset of activity (<6-8 weeks) as compared to immunomodulators (>8-12 weeks). We also included a sensitivity analysis where both infliximab and adalimumab were assumed to have a risk of "low blood counts or liver reaction" as both have been described with anti-TNF therapy in rare cases [17,18], albeit with considerably lower frequency than with azathioprine or methotrexate [19].…”

Section: Discussionmentioning

confidence: 99%

Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment

et al. 2020

View full text Add to dashboard Cite

Objective To quantify patient preferences for maintenance therapy of Crohn's disease and understand the impact on treatment selection. Methods We conducted a discrete-choice experiment in patients with Crohn's disease (n = 155) to measure the importance of attributes relevant to choosing between different medical therapies for maintenance of Crohn's disease. The attributes included efficacy and withdrawals due to adverse events, as well as dosing and other rare risks of treatment. From the discrete-choice experiment we estimated the part-worth (importance) of each attribute level, and explored preference heterogeneity through latent class analysis. We then used the part-worths to apply weights across each outcome from a prior network meta-analysis to estimate patients' preferred treatment in pairwise comparisons and for the overall group of treatments. Results The discrete-choice experiment revealed that maintaining remission was the most important attribute. Patients would accept a rare risk of infection or cancer for a 14% absolute increased chance of remission. Latent class analysis demonstrated that 45% of the cohort was risk averse, either to adverse events or requiring a course of prednisone. When these preferences were used in modelling studies to compare pairs of treatments, there was a � 78% probability that all biologic treatments were preferred to azathioprine and methotrexate,

show abstract

Adverse events in IBD therapy: the 2018 update

Cited by 59 publications

References 122 publications

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

Existing bitter medicines for fighting 2019‐nCoV‐associated infectious diseases

Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment

Contact Info

Product

Resources

About